Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.57
+0.32 (3.12%)
Nov 6, 2026, 4:00 PM EST - Market closed
Monte Rosa Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 45.18 | 129.88 | 224.25 | 128.1 | 54.91 | 346.07 |
Short-Term Investments | 532.55 | 247.22 | 147.9 | 104.31 | 207.91 | - |
Cash & Short-Term Investments | 577.73 | 377.1 | 372.15 | 232.41 | 262.83 | 346.07 |
Cash Growth | 47.66% | 1.33% | 60.12% | -11.57% | -24.05% | 729.93% |
Other Receivables | 57.62 | 11.6 | 0.17 | 0.51 | 7.66 | - |
Receivables | 57.62 | 11.6 | 0.17 | 0.51 | 7.66 | - |
Prepaid Expenses | 4.72 | 4.48 | 5.12 | 3.29 | 4.44 | 2.6 |
Restricted Cash | - | - | - | - | 0.96 | - |
Total Current Assets | 640.07 | 393.19 | 377.44 | 236.21 | 275.89 | 348.67 |
Property, Plant & Equipment | 51.98 | 50.37 | 56.31 | 62.61 | 61.91 | 12.33 |
Other Long-Term Assets | 5.69 | 5.1 | 4.98 | 4.93 | 4.6 | 5.34 |
Total Assets | 697.73 | 448.66 | 438.73 | 303.76 | 342.39 | 366.33 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.35 | 3.55 | 17.22 | 11.15 | 7.86 | 6.56 |
Accrued Expenses | 33.41 | 25.12 | 15.43 | 12.93 | 9.56 | 9.24 |
Current Portion of Leases | 4.19 | 4.4 | 3.71 | 3.16 | 3.13 | - |
Current Unearned Revenue | 21.1 | 29.57 | 117.23 | 17.68 | - | - |
Other Current Liabilities | - | 1.58 | 3.35 | 1.67 | 5.02 | 0.84 |
Total Current Liabilities | 62.05 | 64.21 | 156.95 | 46.59 | 25.57 | 16.64 |
Long-Term Leases | 32.08 | 34.79 | 39 | 42.88 | 43.87 | - |
Long-Term Unearned Revenue | 102.26 | 111.33 | 16.15 | 32.32 | - | - |
Pension & Post-Retirement Benefits | 5.13 | 5.27 | 3.7 | 2.71 | 1.53 | 2.18 |
Total Liabilities | 201.52 | 215.6 | 215.8 | 124.51 | 70.98 | 18.81 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 1,064 | 714.09 | 664.87 | 547.86 | 503.7 | 471.57 |
Retained Earnings | -562.05 | -477.21 | -438.59 | -365.89 | -230.54 | -122.04 |
Comprehensive Income & Other | -6.19 | -3.83 | -3.36 | -2.72 | -1.75 | -2.02 |
Total Common Equity | 496.21 | 233.06 | 222.94 | 179.25 | 271.41 | 347.52 |
Shareholders' Equity | 496.21 | 233.06 | 222.94 | 179.25 | 271.41 | 347.52 |
Total Liabilities & Equity | 697.73 | 448.66 | 438.73 | 303.76 | 342.39 | 366.33 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 36.27 | 39.19 | 42.72 | 46.04 | 47 | - |
Net Cash (Debt) | 541.46 | 337.91 | 329.43 | 186.37 | 215.83 | 346.07 |
Net Cash Growth | 54.22% | 2.57% | 76.76% | -13.65% | -37.64% | 729.93% |
Net Cash Per Share | 5.57 | 4.07 | 4.46 | 3.63 | 4.57 | 13.84 |
Filing Date Shares Outstanding | 85.45 | 80.02 | 61.51 | 50.14 | 49.24 | 46.37 |
Total Common Shares Outstanding | 85.43 | 65.54 | 61.51 | 50.14 | 49.32 | 46.54 |
Working Capital | 578.02 | 328.97 | 220.49 | 189.62 | 250.32 | 332.03 |
Book Value Per Share | 5.81 | 3.56 | 3.62 | 3.57 | 5.50 | 7.47 |
Tangible Book Value | 496.21 | 233.06 | 222.94 | 179.25 | 271.41 | 347.52 |
Tangible Book Value Per Share | 5.81 | 3.56 | 3.62 | 3.57 | 5.50 | 7.47 |
Machinery | - | 29.81 | 27.4 | 24.23 | 18.65 | 13.06 |
Construction In Progress | - | 0.12 | 0.06 | 0.92 | 12.01 | 0.85 |
Leasehold Improvements | - | 23.67 | 22.39 | 20.89 | 2.66 | 1.12 |